Zobrazeno 1 - 6
of 6
pro vyhledávání: '"M S, Austenfeld"'
Publikováno v:
The Prostate. 22:23-30
The expression of the mutant p53 tumor suppressor gene was evaluated in 33 human prostate carcinomas. Using an immunohistochemical method with monoclonal antibodies PAb 1801 and PAb 240, 26 (79%) tumors demonstrated positive immunostaining for mutant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7c50153c885a872c861edd8d8a54719a
https://doi.org/10.1002/pros.2990220104
https://doi.org/10.1002/pros.2990220104
Autor:
R G, Middleton, I M, Thompson, M S, Austenfeld, W H, Cooner, R J, Correa, R P, Gibbons, H C, Miller, J E, Oesterling, M I, Resnick, S R, Smalley
Publikováno v:
The Journal of urology. 154(6)
The American Urological Association convened the Prostate Cancer Clinical Guidelines Panel to analyze the literature regarding available methods for treating locally confined prostate cancer, and to make practice policy recommendations based on the t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::44df558007c1f2a67a51f733668e5d9e
https://pubmed.ncbi.nlm.nih.gov/7500479
https://pubmed.ncbi.nlm.nih.gov/7500479
Autor:
M S, Austenfeld
Publikováno v:
Seminars in urologic oncology. 13(3)
Serum prostate-specific antigen testing and systematic ultrasound-guided biopsy has improved our ability to diagnose low-stage, nonpalpable prostate cancer. With improvement of diagnostic sensitivity, the risk of finding clinically insignificant or "
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c901fa6725c2053dad8c30f845a7604d
https://pubmed.ncbi.nlm.nih.gov/8521129
https://pubmed.ncbi.nlm.nih.gov/8521129
Publikováno v:
The Journal of urology. 152(5 Pt 2)
Medical interventions are identified to be in need of practice guidelines based on several criteria, including uncertainty of therapeutic benefit, economic impact, variation in practice patterns and lack of objective data for new developments. Treatm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::69df76df061a605e7a0306931a159f09
https://pubmed.ncbi.nlm.nih.gov/7933242
https://pubmed.ncbi.nlm.nih.gov/7933242
Autor:
M S, Austenfeld
Publikováno v:
Seminars in urology. 11(2)
Stage A1 prostate cancer implies indolence. If only well-differentiated low-volume tumors are considered, the rate of cancer growth, clinical progression, and prostate cancer death is exceedingly low. All but a very few of these patients will need ob
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c86391631997342f30576f653b02f14a
https://pubmed.ncbi.nlm.nih.gov/7689740
https://pubmed.ncbi.nlm.nih.gov/7689740
Autor:
M S, Austenfeld, B E, Davis
Publikováno v:
The Urologic clinics of North America. 17(4)
Stage D1 disease will be encountered in 20 per cent of patients by those who treat prostate cancer. There is marked heterogeneity among cancers discovered at this stage, with 5-year disease-free survival rates ranging from 0 to 95 per cent. Generally
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2884a2b233d2c603fcd473cf51f59768
https://pubmed.ncbi.nlm.nih.gov/2219583
https://pubmed.ncbi.nlm.nih.gov/2219583